GlassScriptPhysician profile
Mark J Blotcky
NPI 1023123148
$3,488.53
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $468 · 2021: $821 · 2022: $698 · 2023: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $362.26 | 2021-2023 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $338.53 | 2019-2023 | Rexulti |
| Lundbeck LLC | $329.47 | 2019-2023 | Brintellix |
| Bausch Health US, LLC | $284.81 | 2019-2023 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $255.60 | 2019-2023 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $251.63 | 2019-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $223.74 | 2020-2021 | |
| Alkermes, INC. | $202.76 | 2022-2023 | Aristada, Lybalvi |
| Tris Pharma INC | $188.82 | 2019-2023 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.21 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $172.57 | 2019-2022 | |
| Shire North American Group INC | $135.60 | 2019 | |
| Avanir Pharmaceuticals, INC. | $105.85 | 2020-2022 | |
| Corium, LLC | $64.40 | 2023 | Azstarys |
| Allergan, INC. | $64.23 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $54.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $50.04 | 2022-2023 | Belsomra |
| Neurocrine Biosciences, INC. | $49.15 | 2022-2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $41.80 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $33.48 | 2021-2022 | |
| Adlon Therapeutics L.P. | $26.15 | 2020 | |
| Noven Therapeutics, LLC | $20.29 | 2023 | Secuado |
| Vertical Pharmaceuticals, LLC | $15.77 | 2019 | |
| Axsome Therapeutics, INC. | $15.06 | 2022 | |
| Ironshore Pharmaceuticals INC. | $12.30 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Blotcky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.